[{"indications": "Indications\u00a0adjunct to co-beneldopa or co-careldopa in Parkinson\u2019s disease with\r\n\u2018end-of-dose\u2019 motor fluctuations if another inhibitor of peripheral\r\ncatechol-O-methyltransferase inappropriate (under\r\nspecialist supervision)", "name": "TOLCAPONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Catechol-O-methyltransferase inhibitors"], "cautions": "Cautions\u00a0avoid abrupt withdrawal; most patients receiving more than 600\u00a0mg levodopa\r\ndaily require reduction of levodopa dose by about 30%; interactions: Appendix 1 (tolcapone) Hepatotoxicity\u00a0Potentially life-threatening\r\nhepatotoxicity including fulminant hepatitis reported rarely, usually\r\nin women and during the first 6 months, but late-onset liver injury\r\nalso reported; test liver function before\r\ntreatment, and monitor every 2 weeks for first year, every 4 weeks\r\nfor next 6 months and then every 8 weeks thereafter (restart monitoring\r\nschedule if dose increased); discontinue\r\nif abnormal liver function tests or symptoms of liver disorder (counselling, see below); do not re-introduce tolcapone\r\nonce discontinuedCounselling\u00a0Patients should be told\r\nhow to recognise signs of liver disorder and advised to seek immediate\r\nmedical attention if symptoms such as anorexia, nausea, vomiting,\r\nfatigue, abdominal pain, dark urine, or pruritus develop", "side-effects": "Side-effects\u00a0diarrhoea, constipation, dyspepsia, abdominal\r\npain, nausea, vomiting, anorexia, xerostomia, hepatotoxicity (see\r\nabove); chest pain; confusion, dystonia, dyskinesia, drowsiness, headache,\r\ndizziness, sleep disturbances, excessive dreaming, hallucinations;\r\nsyncope; urine discoloration; sweating; neuroleptic malignant syndrome\r\nand rhabdomyolysis reported on dose reduction or withdrawal", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129262.htm", "doses": ["100\u00a0mg 3 times daily, leave 6 hours between each dose;\r\nmax. 200\u00a0mg 3 times daily in exceptional circumstances; first daily\r\ndose should be taken at the same time as levodopa with dopa-decarboxylase\r\ninhibitor", "Continue beyond 3 weeks only if substantial improvement"], "pregnancy": "Pregnancy\u00a0toxicity in animal studies\u2014use only\r\nif potential benefit outweighs risk"}]